DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
Stopped Project delays
Conditions
- Human Papillomavirus-16 Positive
- Human Papillomavirus-18 Positive
- Metastatic Malignant Neoplasm
- Recurrent Anal Canal Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Penile Carcinoma
- Recurrent Vaginal Carcinoma
- Recurrent Vulvar Carcinoma
- Refractory Malignant Neoplasm
- Stage IV Anal Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Vaginal Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Vaginal Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
Interventions
- BIOLOGICAL: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- BIOLOGICAL: Durvalumab
Sponsor
M.D. Anderson Cancer Center
Collaborators